Home › Compare › TGAFF vs ABBV
TGAFF yields 86.38% · ABBV yields 3.06%● Live data
📍 TGAFF pulled ahead of the other in Year 1
Combined, TGAFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TGAFF + ABBV for your $10,000?
Taiga Building Products Ltd. operates as a wholesale distributor of building products in Canada and the United States. It offers composite decking products, railings, and accessories; engineered wood products; laminate and vinyl floorings; insulation products; dimension lumber products; moldings; panels, such as plywood, oriented strand boards, and particleboards; polyethylene sheeting products; and preserved wood products, including fencing, landscape timbers, plywoods, preserved wood foundation, and pre-stained products. The company also provides roofing materials; batt and foam insulation products; siding and trim products; and wall coverings and accessories. In addition, it produces pressure-treated wood products. The company distributes its building products through 15 distribution centers in Canada, 2 distribution centers in the United States to building products retailers, building supply yards, and industrial manufacturers. It also exports its products to Asia, Central America, South America, and the Middle East. The company was founded in 1973 and is headquartered in Burnaby, Canada. Taiga Building Products Ltd. operates as a subsidiary of Avarga Limited.
Full TGAFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.